Tuesday, April 30, 2019

The obscure advisory committees at the heart of the U.S. drug pricing debate

Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries.


from Reuters: U.S. https://reut.rs/2VwZsGQ
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

By Unknown Author from NYT World https://ift.tt/0xmOpRu